1257072-34-6

Basic information

• Product Name: 6-Bromo-3-chloropyrazine-2-carbonitrile
• Synonyms: 6-Bromo-3-chloropyrazine-2-carbonitrile;6-BroMo-3-chloro-2-pyrazinecarbontirile
• CAS NO: 1257072-34-6
• Molecular Formula: C₅HBrClN₃
• Molecular Weight: 218.43854
• Mol File: 1257072-34-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-Bromo-3-chloropyrazine-2-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-3-chloropyrazine-2-carbonitrile(1257072-34-6)
• EPA Substance Registry System: 6-Bromo-3-chloropyrazine-2-carbonitrile(1257072-34-6)

Safety Data

• Hazardous Substances Data: 1257072-34-6(Hazardous Substances Data)

Usage

General Description

6-Bromo-3-chloropyrazine-2-carbonitrile is a chemical compound with the molecular formula C6H2BrClN3. It contains a pyrazine ring with bromine and chlorine substituents at positions 6 and 3, respectively, as well as a cyano group (-CN) at position 2. 6-Bromo-3-chloropyrazine-2-carbonitrile is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has potential applications in the development of pesticides, herbicides, and pharmaceutical drugs due to its unique structure and reactivity. Additionally, 6-Bromo-3-chloropyrazine-2-carbonitrile is also used in research and development laboratories for various chemical reactions and synthetic processes.

Upstream product

• 55321-99-8 3-hydroxy-2-pyrazinecarboxamide 
• 17231-51-5 2-amino-5-bromo-3-cyanopyrazine 

Downstream Products

• 1257072-48-2 chloro-6-(hydroxymethyl)pyrazine-2-carbonitrile 
• 356783-28-3 3,6-difluoropyrazine-2-carbonitrile 
• 259793-96-9 favipiravir 

Relevant articles and documents

The complete synthesis of favipiravir from 2-aminopyrazine

Favipiravir was first synthesized from an inexpensive and commercially available starting material, 2-aminopyrazine. The preferred route embedded within Scheme?4 consisted of seven steps, and was highlighted by the novel and efficient synthesis of 3,6-dichloropyrazine-2-carbonitrile 8. This intermediate was prepared in four successive steps which were regioselective chlorination of the pyrazine ring, bromination, Pd-catalyzed cyanation, and Sandmeyer diazotization/chlorination. This protocol eliminated the hazardous POCl3 of previous synthetic methods and offered a better yield (48%) which was 1.3-fold higher than a recently published procedure. From intermediate 8, the subsequent nucleophilic fluorination, nitrile hydration and hydroxyl substitution efficiently afforded the target product. Another synthetic approach with the same starting material was also investigated to bypass the allergy-causing dichloro intermediate 8. However, the key step of monofluorination at the pyrazine C6 position of intermediate 19 or 22 was not achieved.

Pyrazine derivatives and their use

The invention relates to a pyrazine derivative, or a stereoisomer, a geometrical isomer, a tautomer, a nitric oxide, a hydrate, a solvate, a metabolite and a pharmaceutically acceptable salt or prodrug. The invention also relates to an application of the pyrazine derivative, or the stereoisomer, the geometrical isomer, the tautomer, the nitric oxide, the hydrate, the solvate, the metabolite and the pharmaceutically acceptable salt or prodrug as a medicine, especially an application in preparation of an antiviral drug.

Containing cyclobutane substituent of pyrazines, its composition and use thereof

The invention relates to a pyrazine compound containing a diethylene substituent and application thereof as a medicine, particularly application thereof to preparation of medicines for preventing and treating various influenza viruses. Particularly, the invention relates a compound of which the general formula I is shown in the specification, or a stereoisomer, a geometrical isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and all variables are defined in the specification. The invention also relates to application of the compound of which the general formula I is shown in the specification, or the stereoisomer, the geometrical isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the pharmaceutically acceptable salt or the prodrug thereof as medicines, particularly application of the compound as a medicine for preventing and treating influenza viruses.